Michael Bolton's 'weird' moment that led to brain cancer diagnosis
Michael Bolton's daughters have spoken out about the moment they knew something was wrong with their father - leading to his glioblastoma diagnosis
Michael Bolton's family have revealed they realised something was wrong when the singer made a series of peculiar moves during a bowling night out. The 72-year-old pop star was enjoying a game with his children and grandkids when he exhibited some odd behaviour.
According to People magazine, his daughter Taryn recalled that unsettling moment, saying: "That was when we were like, 'Something's wrong with his brain. Everything that happened was weird for him but not super alarming. When you look back at everything together. . . We missed so many things."
His behaviour at the bowling alley turned out to be red flags for glioblastoma, an uncommon and aggressive type of brain cancer. Symptoms associated with brain tumours can range from persistent headaches and seizures to nausea, fatigue, or even changes in personality and physical abilities, all hinging on the tumour's whereabouts, size, and speed of growth in the brain, reports Surrey Live.
That same evening, yet another abnormal incident worried the family as Michael toppled from his chair. Taryn said: "He fell out of his chair to the left, which is very unusual. He's super athletic, and he doesn't drink. So he fell, and we were like, 'What just happened?'"
That weekend, Bolton experienced a severe headache and by Monday, he found himself in hospital. An MRI scan confirmed the presence of a brain tumour.
The tumour was completely removed during surgery and about a week later, doctors diagnosed it as glioblastoma, a condition that affects roughly 15,000 Americans annually, according to the National Brain Tumor Society. After undergoing two surgeries and several rounds of chemotherapy and radiotherapy, the singer's most recent scan earlier this month showed no signs of the tumour.
In a fresh interview, the singer declared: "Succumbing to the challenge is not an option. You're really quickly drawn into a duel. I guess that's the way you find out what you're made of."
He added: "Whenever you find yourself in any kind of challenging position, just to know that you're not alone going through it is a big deal." He now confesses that his health scare has instilled in him a deeper appreciation for life. His daughter, Holly, disclosed that he began singing "within minutes" while recovering from his operation.
Dr. Ingo Mellinghoff, Bolton's neuro-oncologist at Memorial Sloan Kettering Cancer Center in New York City, explained that symptoms of brain tumours often encompass sudden personality changes, intense headaches, seizures, coordination problems and muscle weakness and paralysis.
"If all of a sudden you're a completely different person, and people are like, 'He never gets out of bed anymore. What's going on? He doesn't want to do anything'...", Mellinghoff says. "If somebody can't move one part of their body, that's never normal. Or changes in sensation. When they say, 'I can't feel anything anymore on my right side.'"
Mellinghoff also points out that alterations in how someone speaks can act as a serious warning sign. "Speech is pretty sensitive. We all have our speech patterns, and if all of a sudden your friend says, 'It sounds so strange, and it doesn't make sense,' that is definitely something," he notes.
"It's really hard to put out the message of, 'If you have a headache, think about brain cancer,' because that's so rare," he remarks. "Many of these symptoms are very non-specific, so we have to be careful not scaring everyone."
The Brains Trust charity has laid out what to watch for when it comes to the deadly illness, writing: "Because there are so many different types of brain tumour, there are a number of brain tumour symptoms and signs, depending on the nature of the brain tumour and where it is."
The continue: "These may be very severe, or may not be apparent at all. So, it is a very broad spectrum with which we are dealing. Please remember this if you haven't been diagnosed with a brain tumour. It is a rare condition and having a headache for more than a week does not mean that you necessarily have a brain tumour."
Brain tumour symptoms
Headaches that are more severe in the morning and wake you in the night. They are usually different from headaches you might have had previously and will be persistent and worsen with time
Nausea and vomiting: With a headache this can indicate increased pressure in the head (raised intracranial pressure)
Seizures: A seizure is abnormal electrical impulses in the brain, causing sudden involuntary changes in movement or function, sensation, awareness, or behaviour. A first-time seizure in an adult is often investigated
Weakness, loss of sensation or numbness: This is a sign of pressure on (or damage to) a specific part of the brain and can also be manifested through walking unsteadily or lack of coordination (ataxia) or muscle weakness on one side of the body (hemiparesis)
Hearing loss: Could be a sign of an acoustic neuroma if it occurs only on one side
Loss/disturbance of vision, including double vision: In one or both eyes could be a symptom, if there is a tumour pressing on the optic nerve or there is one affecting the visual pathways or if there is raised intracranial pressure.
Speech difficulties: May also include the loss of ability to write, speak or understand words. A person may have difficulty getting the right words out (expressive dysphasia) or difficulty articulating them (dysarthia)
Other brain tumour symptoms: Lack of concentration, confusion, memory loss, disorientation, drowsiness, change in behaviour.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
3 hours ago
- Daily Mirror
Boy diagnosed with two cancers before age 3 after parents spotted unusual sign
The family of Felix Disney-Moore, now aged four, from Sandhurst, Berkshire, found themselves relieved the second cancer was leukaemia as it meant the first hadn't spread A mum of a young boy who has had two rare cancers before the age of three has told why she first went to a doctor with him after seeing something unusual. Felix Disney-Moore, now aged four, had no symptoms until his mum, Hayley Disney, 40, spotted a white glow in his left eye and took him for a check-up at Frimley Park Hospital, Surrey. He was urgently referred to Royal London Hospital and diagnosed with bilateral retinoblastoma - a form of eye cancer that affects both eyes - and the family were told he'd need his left eye removed to save his life. But a day before he was due to have his surgery, an MRI revealed a third tumour - and he was diagnosed with trilateral retinoblastoma with leptomeningeal disease instead - and Felix had to undergo eight months of aggressive chemotherapy. The family hoped they were out of the woods but a post-treatment scan three months later picked up a mass on his liver. Tests revealed Felix had lymphoma - a type of blood cancer - and he has spent the last two years undergoing chemotherapy and should finally finish in July. Hayley and Felix's dad, Tom Moore, 44, a retail manager, are fundraising to take Felix and his sister Thea, seven, to Disney World, Florida. Hayley, who previously worked as the head of operations for a digital app, from Sandhurst, Berkshire, said: "I noticed a slight white glow in his eye and thought 'I'll go get it checked out'. "Literally everything changed. He was such a happy baby we thought 'are we going to lose him?'. But he's so amazing. Felix astonishes me everyday. He still has such a zest for life." Hayley suddenly spotted the glow the day after Felix's second birthday in August 2022. She took him to hospital to get it checked out, told he was blind in his left eye, and was then urgently referred to Royal London Hospital. A week later a red reflex test - looking at the back of the eye using a light - revealed Felix had bilateral retinoblastoma and the family had to come to terms with their son losing his left eye to save his life. Hayley said: "You don't have time to process. You just have to do. It was incredibly daunting." But the day before his surgery Hayley received a phone call from Great Ormond Street Hospital (GOSH) telling her a pre-op MRI scan had revealed a third tumour in his pineal gland and a leak into his brain. This meant Felix's new diagnosis was trilateral retinoblastoma and he would need an aggressive chemotherapy instead. Hayley said: "GOSH had seen one other case in the last 10 years - now 12. It was a lot to process. There were no statistics. We had absolutely no clue on success rates. It was really frightening." Felix started on five cycles of chemotherapy in September 2022 - after each cycle he became extremely unwell. After his last 40 day stay on a high dose Felix had a stem cell transplant in March 2023 and the family hoped they would be able to have a normal life again. Hayley said: "We found ourselves in this new world of just waiting, watching every breath Felix took, wondering. But we started to get to life. We went back to work, Felix started to build his strength." But after Felix's post-treatment scan in June 2023 the family were given bad news. Hayley said: "They could see something on his liver." Felix had all sorts of tests including biopsies, lumbar punctures, MRIs and ultrasounds and doctors thought his retinoblastoma had spread which would have meant there was nothing more they could do. Hayley said: "How was I going to explain it to Felix? How do you explain to your child they are going to die? He'd been getting stronger and enjoying life." But the family were relieved when a PET scan revealed it was actually leukaemia - and later reconfirmed as lymphoma - and treatable. Hayley said: "It was a massive shock to them that it came back as treatable. It was feeling very wrong to be celebrating your child has lymphoma. But it was amazing news." Felix had to start more chemotherapy at Southampton Hospital in July 2023. Hayley said: "It hit Felix hard. He'd already gone through this gruelling eight months of high level chemotherapy. He gained a lot of weight and he stopped walking." Felix has been going through chemotherapy for the last two years - and also faced a sepsis scare when his port became infected - but is now nearing the end of treatment in July 2025. He has been left with damaged hearing due to treatment and will have to wear a hearing aid for the rest of his life but has always kept a smile on his face. Hayley now wants to give some normality back to her children and treat them to a trip to Disney World. But the family have run out of savings after using what they had squirrelled away over the last few years. Their friends have set up a fundraiser to raise money to get the family on holiday following the end of Felix's treatment - as Hayley still fears the cancer could return. Hayley said: "They deserve the world. It's a massive chunk of their childhood taken away. They deserve something fun. I want something special for them."
NBC News
4 hours ago
- NBC News
Two patients faced chemo. The one who survived got a test to see if it was safe.
JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her. Six days later, Zembruski-Ruple went to Sloan Kettering's urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. 'Enzyme deficiency,' Zembruski-Ruple texted a friend. The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home. Covered in bruises and unable to swallow or talk, she eventually entered hospice care and died March 25 from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among about 1,300 Americans each year who die from the toxic effects of that pill or its cousin, the IV drug fluorouracil known as 5-FU. Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it's expensive and must be administered within four days of the first chemotherapy treatment. Newer cancer drugs sometimes include a companion diagnostic to determine whether a drug works with an individual patient's genetics. But 5-FU went on the market in 1962 and sells for about $17 a dose; producers of its generic aren't seeking approval for toxicity tests, which typically cost hundreds of dollars. Doctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco. By the time Zembruski-Ruple's doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal. Khavkine said he 'would have asked for the test' if he had known about it, but added 'nobody told us about the possibility of this deficiency.' Zembruski-Ruple's sister also said she wasn't warned about the fatal risks of the chemo, or told about the test. 'They never said why they didn't test her,' Zembruski said. 'If the test existed, they should have said there is a test. If they said, 'Insurance won't cover it,' I would have said, 'Here's my credit card.' We should have known about it.' Guidance moves at a glacial pace Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives who push for routine testing of all patients before they take the drug, the medical establishment has moved slowly. A panel of the National Comprehensive Cancer Network, or NCCN — specialists from Sloan Kettering and other top research centers — until recently did not recommend testing, and the FDA does not require it. In response to a query from KFF Health News about its policy, Sloan Kettering spokesperson Courtney Nowak said the hospital treats patients 'in accordance with NCCN guidelines.' She said the hospital would not discuss a patient's care. On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to 'inform patients prior to treatment' about the risks of taking 5-FU and capecitabine. On March 31 — six days after Zembruski-Ruple's death — the network's expert panel for most gastrointestinal cancers took a first step toward recommending testing for the deficiency. Worried that President Donald Trump's FDA might do nothing, Venook said, the panel — whose guidance shapes the practices of oncologists and health insurers — recommended that doctors consider testing before dosing patients with 5-FU or capecitabine. However, its guidance stated that 'no specific test is recommended at this time,' citing a lack of data to 'inform dose adjustments.' Sloan Kettering 'will consider this guidance in developing personalized treatment plans for each patient,' Nowak told KFF Health News. The new NCCN guidance was 'not the blanket recommendation we were working toward, but it is a major step toward our ultimate goal,' said Kerin Milesky, a public health official in Brewster, Massachusetts, who's part of an advocacy group for testing. Her husband, Larry, died two years ago at age 73 after a single treatment of capecitabine. European drug regulators began urging oncologists to test patients for deficiency in May 2020. Patients with potentially risky genetics are started on a half-dose of the cancer drug. If they suffer no major toxicity, the dose is increased. A lifesaving ultimatum? Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn't do deficiency testing, but Alimonti insisted. 'Nope,' she said. 'I'm not starting it until I get the test back.' The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she's had to skip doses because of low white blood cell counts, Alimonti said. She still doesn't know whether her insurer will cover the test. Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers. At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel's co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test 'without saying what to do with the result.' But Richard Pazdur, the FDA's top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. 'If you don't have the information, how do you have counseling?' he asked. Two months later, Venook's panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA's ability to further confront the issue spurred the panel's change of heart, he said. 'I don't know if FDA is going to exist tomorrow,' Venook told KFF Health News. 'They're taking a wrecking ball to common sense, and that's one of the reasons we felt we had to go forward.' On May 20, the FDA posted a Federal Register notice seeking public input on the issue, a move that suggested it was considering further action. Venook said he often tests his own patients, but the results can be fuzzy. If the test finds two copies of certain dangerous gene variants in a patient, he avoids using the drug. But such cases are rare — and Zembruski-Ruple was one of them, according to her sister and Khavkine. Many more patients have a single copy of a suspect gene, an ambiguous result that requires clinical judgment to assess, Venook said. A full-gene scan would provide more information but adds expense and time, and even then the answer may be murky, Venook said. He worries that starting patients on lower doses could mean fewer cures, especially for newly diagnosed colon cancer patients. Power Should Rest With Patients Scott Kapoor, a Toronto-area emergency room physician whose brother Anil, a much-loved urologist and surgeon, died of 5-FU toxicity at age 58 in 2023, views Venook's arguments as medical paternalism. Patients should decide whether to test and what to do with the results, he said. 'What's better — don't tell the patient about the test, don't test them, potentially kill them in 20 days?' he said. 'Or tell them about the testing while warning that potentially the cancer will kill them in a year?' 'People say oncologists don't know what to do with the information,' said Karen Merritt, whose mother died after an infusion of 5-FU in 2014. 'Well, I'm not a doctor, but I can understand the Mayo Clinic report on it.' The Mayo Clinic recommends starting patients on half a dose if they have one suspect gene variant. And 'the vast majority of patients will be able to start treatment without delays,' Daniel Hertz, a clinical pharmacologist from the University of Michigan, said at the January meeting. Some hospitals began testing after patients died because of the deficiency, said Lindsay Murray, of Andover, Massachusetts, who has advocated for widespread testing since her mother was treated with capecitabine and died in 2021. In some cases, Venook said, relatives of dead patients have sued hospitals, leading to settlements. Kapoor said his brother — like many patients of non-European origin — had a gene variant that hasn't been widely studied and isn't included in most tests. But a full-gene scan would have detected it, Kapoor said, and such scans can also be done for a few hundred dollars. The cancer network panel's changed language is disappointing, he said, though 'better than nothing.' In video tributes to Zembruski-Ruple, her friends, colleagues, and clients remembered her as kind, helpful, and engaging. 'JoEllen was beautiful both inside and out,' said Barbara McKeon, a former colleague at the MS Society. 'She was funny, creative, had a great sense of style.' 'JoEllen had this balance of classy and playful misbehavior,' psychotherapist Anastatia Fabris said. 'My beautiful, vibrant, funny, and loving friend JoEllen.'
Daily Mirror
11 hours ago
- Daily Mirror
Lip sign could mean you're '80% more likely to get dementia'
A study has found that a certain virus that can manifest on the lips could indicate a heightened risk of developing Alzheimer's disease. A symptom appearing on the lips could potentially signal an increased risk of developing dementia, according to recent research. This viral symptom has been linked with an 80 per cent increased risk of Alzheimer's disease. The study, published in the British Medical Journal, suggests that the herpes simplex virus type 1 (HSV-1), a common virus responsible for herpes and cold sores, may contribute to the onset of Alzheimer's. While previous studies have hinted at a link between HSV-1 and Alzheimer's, this research aimed to delve deeper into this association. As part of the study, researchers analysed the medical records of over 300,000 individuals aged 50 and above. As reported by SurreyLive, participants were split into two equal groups, distinguished by those diagnosed with Alzheimer's disease and those without such a diagnosis. Alzheimer's Research UK detailed how the study found that 1,507 (0.44 per cent) of participants diagnosed with Alzheimer's disease had a history of HSV-1 infection, compared with 823 (0.22 per cent) without an Alzheimer's diagnosis. The conclusion drawn was that individuals with an HSV-1 infection had an 80 per cent increased risk of Alzheimer's. This remained true even when other factors, such as carrying two copies of the APOE4 gene, a known risk factor for Alzheimer's, were taken into account. Furthermore, individuals who had been prescribed medication to treat the virus were found to be 17 per cent less likely to develop Alzheimer's compared to those not on any medication. Limits of the study Nevertheless, it's essential to consider some constraints of this study. Dr Sheona Scales, director of Research at Alzheimer's Research UK, highlighted: "Despite the large sample size, this research is based on information gathered from using health records and administrative claims data, which often are based on people self-reporting their conditions. "Most people infected with HSV-1 don't have any symptoms so some infections might not have been recorded. Infections predating the information recorded are also not available. Although cases were matched with controls, diagnosing Alzheimer's disease, especially in the early stages, remains a challenge." While HSV-1 is common, contracting the virus does not guarantee that an individual will develop Alzheimer's disease. The precise relationship between HSV-1 and a heightened risk of Alzheimer's is still under investigation, with current hypotheses suggesting that infections may trigger brain inflammation, potentially leading to damage. Dr Scales further stated: "We know there are 14 lifestyle and environmental risk factors for dementia, and there's not enough evidence to include infections in this list. "This study doesn't tell us if infections are causing the risk, it only shows an association. Further research is needed to understand what the underlying biology around this is." Alzheimer's disease is the most prevalent form of dementia worldwide, accounting for an estimated 80 per cent of all dementia cases.
